Calmark's trial at Södersjukhuset completed
Calmark Sweden AB (publ) announces today that the clinical trial with the product Neo-Bilirubin, which commenced in September 2021 in cooperation with the research entity of the children's hospital Sachsska barn- och ungdomssjukhuset, Södersjukhuset AB, Stockholm, is now successfully completed. All patients have been included and all that remains now is to prepare the final report. Monitoring of the trial was conducted by Scandiavian CRO.The study was conducted at SÖS during the winter months, with an intermission due to the RSV outbreak. Infants with suspected elevated levels of bilirubin